Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabies immune globulin (human) is a sterile solution of immunoglobulins derived from the plasma of human donors hyperimmunized with rabies vaccine. It is used for passive, transient post-exposure prophylaxis of rabies infection in individuals exposed to the virus, providing immediate antibodies until the patient’s own immune system can respond to active vaccination. The drug acts by neutralizing the rabies virus at the site of exposure and in circulation, thereby preventing viral entry into nerve tissue and subsequent progression to clinical disease. It does not replace vaccination but is administered concurrently with a full course of rabies vaccine for optimal protection[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies immune globulin (human).